Martin Jensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Jensen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Anne Gulbech Ording
Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
2 shared publications - Peter Brønnum Nielsen
Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark
2 shared publications Anette Arbjerg Højen
Department of Cardiology (M.S., M.J., A.A.H., T.B.L., A.G.O., P.B.N.), Aalborg University Hospital, Denmark
1 shared publication- Charlotte Brix Andersson
Department of Obstetrics and Gynecology The North Denmark Regional Hospital Thisted Thisted Denmark
1 shared publication - Daniel El Fassi
Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
1 shared publication - Dennis Lund Hansen
Department of Hematology, Odense University Hospital, Odense, Denmark
1 shared publication
Latest Publications
- Open Access
- 30 March 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 210-218
Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study
Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the Danish Pathology Registry. A total of 325 cases were identified. The incidence increased from 0.82 per 1 million person‐years (1 M‐PY) (95% CI 0.61–1.04) in 2000–2011 to 4.05 per 1 M‐PY (95% CI 3.56–4.53) in 2012–2023. Hematologic malignancies were the triggering diagnosis in 46% of cases, mostly lymphomas (32%). There was no clear improvement in overall survival over time. However, survival differed markedly between subgroups, with the lowest 1‐year overall survival of 31% for hematologic malignancy–associated HLH, compared with 75% for idiopathic HLH. In conclusion, HLH remains a rare syndrome with a dismal prognosis, especially when associated with hematologic malignancy.
- 30 March 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (1) , 210-218
Open AccessIncidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study
Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the Danish Pathology Registry. A total of 325 cases were identified. The incidence increased from 0.82 per 1 million person‐years (1 M‐PY) (95% CI 0.61–1.04) in 2000–2011 to 4.05 per 1 M‐PY (95% CI 3.56–4.53) in 2012–2023. Hematologic malignancies were the triggering diagnosis in 46% of cases, mostly lymphomas (32%). There was no clear improvement in overall survival over time. However, survival differed markedly between subgroups, with the lowest 1‐year overall survival of 31% for hematologic malignancy–associated HLH, compared with 75% for idiopathic HLH. In conclusion, HLH remains a rare syndrome with a dismal prognosis, especially when associated with hematologic malignancy.
- Open Access
Measurement properties of the Knee Injury and Osteoarthritis Outcome Score (KOOS) for patella fractures
- 1 February 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (2) , 413-422
Net Clinical Benefit of Oral Anticoagulation Among Frail Patients With Atrial Fibrillation: Nationwide Cohort Study
BACKGROUND: Frail people with atrial fibrillation are often undertreated with oral anticoagulants (OACs), and evidence for the net clinical benefit (NCB) of OAC is sparse. We, therefore, examined the risk of thromboembolic events, major bleeding, and NCB of anticoagulation treatment. METHODS: This was a nationwide cohort study including frail patients aged with incident atrial fibrillation between 2013 and 2018. Patients were categorized according to OAC treatment exposure. One-year risks of thromboembolic events and major bleeding were ascertained where death was treated as a competing risk. The NCB of anticoagulation was assessed by a bivariate trade-off between thromboembolism and bleeding. RESULTS: We identified 36 223 frail patients with atrial fibrillation (median age, 79 years; 50.5% female), of whom 61.8% started OAC therapy, while 38.2% were untreated despite indication for stroke prevention. At 1 year, the risk of thromboembolic events was 2.1% (95% CI, 1.8%–2.3%) among patients not receiving OAC versus 1.5% (95% CI, 1.4%–1.7%) in patients with OAC. The bleeding risk was 3.2% (95% CI, 2.9%–3.5%) among patients without OAC versus 3.5% (95% CI, 3.2%–3.8%) among anticoagulated patients. The NCB was 0.70% (95% CI, 0.32%–1.08%), suggesting a benefit of OAC treatment; however, the NCB declined with age and increasing frailty and was lowest among patients >75 years of age or with high frailty level. CONCLUSIONS: Frail patients with atrial fibrillation are often untreated with OAC in routine clinical care despite an indication for stroke prevention. The NCB balancing thromboembolic events and major bleeding was in favor of anticoagulation but decreased with advancing age and increasing frailty.
- 1 February 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (2) , 413-422
Net Clinical Benefit of Oral Anticoagulation Among Frail Patients With Atrial Fibrillation: Nationwide Cohort Study
BACKGROUND: Frail people with atrial fibrillation are often undertreated with oral anticoagulants (OACs), and evidence for the net clinical benefit (NCB) of OAC is sparse. We, therefore, examined the risk of thromboembolic events, major bleeding, and NCB of anticoagulation treatment. METHODS: This was a nationwide cohort study including frail patients aged with incident atrial fibrillation between 2013 and 2018. Patients were categorized according to OAC treatment exposure. One-year risks of thromboembolic events and major bleeding were ascertained where death was treated as a competing risk. The NCB of anticoagulation was assessed by a bivariate trade-off between thromboembolism and bleeding. RESULTS: We identified 36 223 frail patients with atrial fibrillation (median age, 79 years; 50.5% female), of whom 61.8% started OAC therapy, while 38.2% were untreated despite indication for stroke prevention. At 1 year, the risk of thromboembolic events was 2.1% (95% CI, 1.8%–2.3%) among patients not receiving OAC versus 1.5% (95% CI, 1.4%–1.7%) in patients with OAC. The bleeding risk was 3.2% (95% CI, 2.9%–3.5%) among patients without OAC versus 3.5% (95% CI, 3.2%–3.8%) among anticoagulated patients. The NCB was 0.70% (95% CI, 0.32%–1.08%), suggesting a benefit of OAC treatment; however, the NCB declined with age and increasing frailty and was lowest among patients >75 years of age or with high frailty level. CONCLUSIONS: Frail patients with atrial fibrillation are often untreated with OAC in routine clinical care despite an indication for stroke prevention. The NCB balancing thromboembolic events and major bleeding was in favor of anticoagulation but decreased with advancing age and increasing frailty.
- Open Access
- 6 December 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (2) , 200-211
Risk of complications in the late vs early days of the 42nd week of pregnancy: A nationwide cohort study
Introduction: Uncertainty remains about the most appropriate timing of induction of labor in late‐term pregnancies. To address this issue, this study aimed to compare the risk of neonatal morbidity and pregnancy‐ and birth‐related complications between gestational age (GA) 41+4–42+0 and GA 41+0–41+3 weeks.Material and methods: This nationwide registry‐based cohort study included singleton births without major congenital malformations, with registered GA, and with intended vaginal delivery at GA 41+0– 42+0 weeks between 2009 and 2018 in Denmark. Logistic regression models were used to estimate the crude risk ratio and adjusted risk ratio (RRA) of neonatal and obstetric adverse outcomes in births at GA 41+4– 42+0 weeks compared with GA 41+0– 41+3 weeks. The results were adjusted for relevant confounders, including induction of labor.Results: A higher incidence of neonatal morbidity and birth complications was observed in births at GA 41+4–42+0 weeks than in births at GA 41+0–41+3 weeks. Neonatal morbidities included an increased risk of low Apgar score (Apgar 0–6 after 5 min; RRA 1.17, 95% confidence interval [CI] 1.01–1.34), meconium aspiration (RRA 1.25, 95% CI 1.06–1.48), need for respiratory support (continuous positive airway pressure; RRA 1.09, 95% CI 1.03–1.15), and a composite outcome of need for comprehensive treatment at a neonatal department or neonatal death (RRA 1.65, 95% CI 1.29–2.11). Birth complications included emergency cesarean section (RRA 1.17, 95% CI 1.14–1.21), severe lacerations (RRA 1.11, 95% Cl 1.04–1.17), and increased blood loss after birth (RRA 1.13, 95% CI 1.06–1.21).Conclusions: Births at GA 41+4–42+0 weeks were associated with an increased risk of neonatal morbidity and birth complications compared with births at GA 41+0–41+3 weeks. The results of this study may aid clinicians in deciding when to recommend induction of labor in late‐term pregnancies.
- 6 December 2021
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 101 (2) , 200-211
Open AccessRisk of complications in the late vs early days of the 42nd week of pregnancy: A nationwide cohort study
Introduction: Uncertainty remains about the most appropriate timing of induction of labor in late‐term pregnancies. To address this issue, this study aimed to compare the risk of neonatal morbidity and pregnancy‐ and birth‐related complications between gestational age (GA) 41+4–42+0 and GA 41+0–41+3 weeks.Material and methods: This nationwide registry‐based cohort study included singleton births without major congenital malformations, with registered GA, and with intended vaginal delivery at GA 41+0– 42+0 weeks between 2009 and 2018 in Denmark. Logistic regression models were used to estimate the crude risk ratio and adjusted risk ratio (RRA) of neonatal and obstetric adverse outcomes in births at GA 41+4– 42+0 weeks compared with GA 41+0– 41+3 weeks. The results were adjusted for relevant confounders, including induction of labor.Results: A higher incidence of neonatal morbidity and birth complications was observed in births at GA 41+4–42+0 weeks than in births at GA 41+0–41+3 weeks. Neonatal morbidities included an increased risk of low Apgar score (Apgar 0–6 after 5 min; RRA 1.17, 95% confidence interval [CI] 1.01–1.34), meconium aspiration (RRA 1.25, 95% CI 1.06–1.48), need for respiratory support (continuous positive airway pressure; RRA 1.09, 95% CI 1.03–1.15), and a composite outcome of need for comprehensive treatment at a neonatal department or neonatal death (RRA 1.65, 95% CI 1.29–2.11). Birth complications included emergency cesarean section (RRA 1.17, 95% CI 1.14–1.21), severe lacerations (RRA 1.11, 95% Cl 1.04–1.17), and increased blood loss after birth (RRA 1.13, 95% CI 1.06–1.21).Conclusions: Births at GA 41+4–42+0 weeks were associated with an increased risk of neonatal morbidity and birth complications compared with births at GA 41+0–41+3 weeks. The results of this study may aid clinicians in deciding when to recommend induction of labor in late‐term pregnancies.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study
Background and purpose: The effectiveness and safety of edoxaban 60 mg and 30 mg for stroke prevention compared with warfarin in patients with atrial fibrillation (AF) has not been well-described in a nationwide cohort of Caucasian patients treated in standard clinical practice. Methods: We used Danish nationwide registries to identify patients with AF during June 2016 and November 2018 who were treated with edoxaban or warfarin and computed rates per 100 person-years of thromboembolic, all-cause mortality, and bleeding events using an inverse probability of treatment weighting approach to account for baseline confounding. We used weighted pooled logistic regression to compute hazard ratios (HRs) with 95% confidence intervals (CIs) comparing events between edoxaban 60 mg and warfarin users; edoxaban 30 mg was not included in formal comparisons. Results: We identified 6451 AF patients, mean age was 72 years and 40% were females. A total of 1772 patients were treated with edoxaban 60 mg, 537 with edoxaban 30 mg, and 4142 with warfarin. The median CHA2DS2-VASc score was similar between warfarin and edoxaban 60 mg with a score of 3 (interquartile range [IQR] 2–4). In the inverse probability of treatment-weighted pseudo-population, the thromboembolic event rate for edoxaban 60 mg was 0.95 and 1.0 for warfarin, corresponding weighted HR of 1.00 (95% confidence intervals [CI] 0.59, 1.71); see Figure. Edoxaban 60 mg users were associated with lower rates of all-cause mortality (3.93) compared to warfarin (6.04), with a HR of 0.64 (95% CI 0.47 to 0.88). The event rates for bleeding were 3.36 and 3.14, respectively; HR 1.09 (95% CI 0.77, 1.57) Conclusion: Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for white European patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality. Funding Acknowledgement: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This work was supported by an unrestricted research grant from Daiichi-Sankyo Europe GmbH. This funding source had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results.
- 1 October 2021
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (Supplement)
Comparative effectiveness and safety of edoxaban vs warfarin in patients with atrial fibrillation: a nationwide cohort study
Background and purpose: The effectiveness and safety of edoxaban 60 mg and 30 mg for stroke prevention compared with warfarin in patients with atrial fibrillation (AF) has not been well-described in a nationwide cohort of Caucasian patients treated in standard clinical practice. Methods: We used Danish nationwide registries to identify patients with AF during June 2016 and November 2018 who were treated with edoxaban or warfarin and computed rates per 100 person-years of thromboembolic, all-cause mortality, and bleeding events using an inverse probability of treatment weighting approach to account for baseline confounding. We used weighted pooled logistic regression to compute hazard ratios (HRs) with 95% confidence intervals (CIs) comparing events between edoxaban 60 mg and warfarin users; edoxaban 30 mg was not included in formal comparisons. Results: We identified 6451 AF patients, mean age was 72 years and 40% were females. A total of 1772 patients were treated with edoxaban 60 mg, 537 with edoxaban 30 mg, and 4142 with warfarin. The median CHA2DS2-VASc score was similar between warfarin and edoxaban 60 mg with a score of 3 (interquartile range [IQR] 2–4). In the inverse probability of treatment-weighted pseudo-population, the thromboembolic event rate for edoxaban 60 mg was 0.95 and 1.0 for warfarin, corresponding weighted HR of 1.00 (95% confidence intervals [CI] 0.59, 1.71); see Figure. Edoxaban 60 mg users were associated with lower rates of all-cause mortality (3.93) compared to warfarin (6.04), with a HR of 0.64 (95% CI 0.47 to 0.88). The event rates for bleeding were 3.36 and 3.14, respectively; HR 1.09 (95% CI 0.77, 1.57) Conclusion: Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in routine clinical care for white European patients with AF, with non-significantly different risks for stroke and clinically relevant bleeding, but lower all-cause mortality. Funding Acknowledgement: Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): This work was supported by an unrestricted research grant from Daiichi-Sankyo Europe GmbH. This funding source had no role in the design of this study, its execution, analyses, interpretation of the data, or decision to submit results.